AzTrials
AzTrials

Postoperative PainNCT06051630

Effects of Perioperative Administration of Intravenous Lidocaine in Children Operated on for Acute Generalized Peritonitis

A study testing Lidocaine intravenous and Serum saline intravenous in people with Postoperative Pain, run by Université NAZI BONI.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Intravenous administration of lidocaine perioperatively after laparotomy for peritonitis could be an interesting alternative by reducing the duration of postoperative ileus, the intensity of pain and the patient's hospital stay, as well as the cost of management in our context of lack of financial, technical and human… Read more about this study

Who is it for?
Ages 6 to 15 yearsHealthy volunteers can take part
Conditions the study is for
Postoperative Pain
What is being tested?
Lidocaine intravenous and Serum saline intravenous
Type of treatment
Injection or infusion
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
62 participants
Where
No sites listed yet
Study dates
1 Oct 2023to 1 Jan 2024
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 6 to 15 years
  • All sexes
  • Healthy volunteers accepted
  • Child

Who may be able to join

  • All patients aged 6 to 15, Classified according to the American Society of Anaesthesiologists (ASA) (I, II and III) admitted for peritonitis and whose parents have given informed consent

Who cannot join

  • State of shock
  • Severe renal insufficiency (creatinine clearance less than 30 ml/min)
  • History of allergy to lidocaine
  • Refusal to participate in the study

Trial locations and contacts

No sites are listed yet.

Bertille KI, Doctor contact

+22670230257

bertilleki@yahoo.fr

Ismael GUIBLA, Doctor contact

+22676135113

ismaelguibla@gmail.com

About this study

Intravenous administration of lidocaine perioperatively after laparotomy for peritonitis could be an interesting alternative by reducing the duration of postoperative ileus, the intensity of pain and the patient's hospital stay, as well as the cost of management in our context of lack of financial, technical and human resources, hence the present study.

Being tested
Lidocaine intravenous, Serum saline intravenous
Keywords
Peritonitis, Postoperative pain, Lidocaine, Burkina Faso
Medical subject headings
Pain, Postoperative, Peritonitis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Lidocaine intravenousDrug

    Perioperative lidocaine intravenous administration

  • Serum saline intravenousDrug

    Perioperative serum saline intravenous administration

Study groups in NCT06051630
Study groupRoleWhat they receive
Lidocaine groupExperimentalThe group will receive 1.5 mg/kg lidocaine 2% bolus, followed by a continuous electric syringe dose of 1.5 mg/kg/hour intraoperatively, then 1.5 mg/kg/hour during the first 24 hours postoperatively
Receives: Drug: Lidocaine intravenous
Saline groupPlacebo comparatorThe control group will receive an equivalent volume of saline: the volume of saline to be administered will be obtained by considering the dose of lidocaine 2% that the patient would have received if he/she had been in the interventional group.
Receives: Drug: Serum saline intravenous

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Resumption of transit

    time to first gas and/or presence of bowel sounds

    Measured: Up to 7 days during the postoperative period. From the date of randomization to the first postoperative gas and/or the presence of postoperative bowel sounds in the patient

Secondary outcomes (4)
  1. Analog visual scale

    Average pain score, minimal value is 0, maximal value is 10 and higher score mean worse

    Measured: Postoperative pain scores at 24 hours

  2. Concentration of C-reactive protein

    Average of C-reactive protein

    Measured: Hours 24 postoperative

  3. Hospitalisation

    Number of days in hospital

    Measured: Up to 30 days during the postoperative period. From the date of randomization to the patient's discharge from hospital or date of death

  4. Postoperative mortality

    Number of postoperative deaths

    Measured: Up to 30 days during the postoperative period. From date of randomization to date of death

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted25 Sep 2023
  2. Study start1 Oct 2023 (estimated)
  3. Primary completion1 Nov 2023 (estimated)
  4. Study completion1 Jan 2024 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Other
Allocation
Randomised
Intervention model
Parallel groups
Model description
This will be a randomized, double-blind clinical trial conducted at University hospital Charles De Gaulle of Ouagadougou, comparing the results of intravenous administration of lidocaine perioperatively versus administration of saline
Masking
Single blind
Who is masked
Participant
Enrolment
62 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06051630
Sponsor's protocol ID
INSSA 3
Status last verified
Sep 2023
First submitted
21 Aug 2023
Last updated
25 Sep 2023
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Lidocaine intravenous and Serum saline intravenous in people with Postoperative Pain, run by Université NAZI BONI.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 25 Sep 2023. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Bertille KI, Doctor (+22670230257, bertilleki@yahoo.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Resumption of transit (time frame: Up to 7 days during the postoperative period. From the date of randomization to the first postoperative gas and/or the presence of postoperative bowel sounds in the patient). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Sep 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in